רווח תפעולי לפני ניכוי פחת: Scinai Immunotherapeutics Ltd. (SCNI)

Adjusted EBITDA demonstrates current profit trends, where the 0.00 mark characterizes this parameter. The current financial health of Scinai Immunotherapeutics (SCNI) is constrained by a net income deficit resulting from a strategic shift toward CDMO services. However, its own full-cycle Israeli plant guarantees production autonomy, while the development of universal nanobodies provides colossal scaling potential for vaccination with minimal unit costs.

Absolute operating profit measures the actual cash flow from core operations before depreciation and interest, allowing investors to filter out market noise and assess the true efficiency of the business. By analyzing the monthly EBITDA dynamics, one can determine the ability of Scinai Immunotherapeutics (SCNI) to service a high debt load and minimize risks associated with dependence on external contract manufacturing of nanobodies.